SecBot SecBot

MENS

Jyong Biotech Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001954488 Biotech & Drug Discovery
$1.77 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $1.77
Market cap
$132.3M
Micro cap
1 year
−96.5%
from $50.00 · Oct 27
30 days
−10.2%
from $1.97
52-week range
$1.46–50.02
−96% from high · low Feb 11
Avg volume 20D
43.1K
Oct 15 spike 142.6K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BEARISH 2 reports · latest
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BEARISH Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company has a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
HRT FINANCIAL LPDOUBLED50,423$104.0K
UBS Group AGNEAR_EXIT4,046$8.4K
BNP PARIBAS FINANCIAL MARKETSADD2,710$5.6K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 23, 2026
Press release
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven…
May 15, 2026
Earnings
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven…
Apr 28, 2026
Press release
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven…
Mar 27, 2026
Press release
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven…

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 23, 2026 Other
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
New Taipei City, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "C
Jun 30, 2026 Inst.
HRT FINANCIAL LP — DOUBLED
50,423 shares ($104.0K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
4,046 shares ($8.4K)
May 15, 2026 SEC
Jyong Biotech filed its FY2025 annual report on Form 20-F, a routine regulatory milestone. The press release contains…
PRESS-RELEASE — Impact 2/10
May 14, 2026 SEC
Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company has a net loss of…
20-F — Impact 8/10

SecBot reports

2 filings · 0 bullish · 1 bearish · 1 neutral
All MENS filing & press-release reports (2)